Prof Kausik Ray FMedSci

@lamcardio @SVRaoMD Ohh no ! That is awful. I am glad you are safe

⚠️ Trigger warning: this post contains details of a physical assault. I was sadly attacked by a stranger while walking alone at noon from yoga to my hotel in Minneapolis this week. I was strangled and escaped only by a miracle. It was traumatic to say the least.

I don't know these guys (John and Calvin). Never met them. Never even exchanged a word. But wow they nailed it. All you need to know here is that the LMHR crew actually produced a feature-length documentary on the study before the study was even complete. I have wasted far too many words on this garbage dump so instead of wasting more, I will let someone way more articulate say it instead.... youtube.com/watch?v=wE0BQD… I strongly think that no clinical or medical decision should be based on these crude, unadjusted exploratory models. And even then, an author of this study described the finding that LDL-C exposure and ApoB levels were not associated with plaque progression as “incredibly robust.” This characterization is statistically indefensible and clinically irresponsible. This is not a subtle disagreement over interpretation. It is a basic misunderstanding of no-association results—or it’s just spin for that claim. The design is not robust. The exposure definition is not robust. The measurements are not robust. The statistical modeling is not robust. The null inference is not robust. The reporting is not robust. The interpretation is not robust. And the conclusion is not robust. There’s nothing remotely robust about this finding except the author’s insistence that it is. And this definitely raises some serious questions. This study does not meet basic statistical standards and cannot support the claim that LDL-C exposure or ApoB did not predict plaque progression. The paper’s statistical case is a complete shambles. It is fatally flawed, statistically indefensible, and actively misleading. And remember, this is the scientific foundation of The Cholesterol Code documentary, promoted as being grounded in science. Well, this is the kind of science it’s grounded in. How do I drop this mic?

@CMichaelGibson Nice pic! @CMichaelGibson don’t be the guy wearing the mic that then goes to the rest room …..worst still when an emeritus prof with a prostate problem did that 😂😂😂

⛔️ ⚠️ WARNING I am “that guy” who forgets to take his microphone off after a talk at a conference and get into an Uber If you value your microphone, grab me when I step off the podium I’m such a goof

Back to nature, whales , dolphins, sea otters, pelicans and much more. No blue whales yet just humpbacks but we are hopeful Seafood Mexican food and buttery Cali Chardonnay Bliss . Recharging nicely

@SvatiShah @NPagidipati @DukeHeartCenter @manesh_patelMD @robmentz @schuyler_jones @DrCaliff_FDA @Nishant_ShahMD @camfrazmills @ChiadiNdumele @pamelasdouglas Huge congratulations

Congratulations to two of the most incredible leaders I know! @NPagidipati is the new @DukeHeartCenter Section Chief of #preventivecardiology. She has a bold vision for clinical care and research of preventive approaches to reduce CVD burden

Hope you enjoy this CME I did working with PeerVoice. It’s easy in asymptomatic individuals to delay intensification of preventive strategies. A few examples of what we should consider as part of shared decision making

@ayezakhanam121 Wisteria and Agapanthus

@ProfKausikRay Beautiful garden Which flowers or plants are your favorite to grow there?

The garden is looking might fine

It’s all too much for George

And another

@drlucyhooper @DrDerekConnolly @PCCS_UK @BritishCardioSo @ESC_Journals @bacpr @AtrialFibUK @cpgale3 @DrRaniKhatib @GoggleDocs I think we need both if we are to get serious about prevention which is all about early intervention with a long term view. Genes, risk factors and time. Then we need to educate doctors and patients on how to interpret these and what to action. Lots to do.

@DrDerekConnolly @PCCS_UK @BritishCardioSo @ESC_Journals @bacpr @AtrialFibUK @ProfKausikRay @cpgale3 @DrRaniKhatib @GoggleDocs Sorry to see only one mention for lipoprotein (a). And that only related to treatment. Nothing on bringing it into routine screening in the UK. I would place it above PRS as a priority for implementation in primary care.

UK MSF is released 🇬🇧 & is good gov.uk/government/pub… The opportunity is clear & benefits are substantial • 1000s of lives saved • fewer families affected by preventable illness • a more sustainable health & care system • an economic boost; more people able to stay in work

Santorini is a landmark study, the first to study lipid lowering since the 2019 ESC/EAS guidelines. Here we present LLT management and goals attained by glycaemia status. perceptions of risk matter and we manage those with DM better, but not good enough. bmjopen.bmj.com/content/bmjope…

Here is our take in AJPC on using opportunistic tests done for other reasons which suggest calcification and hence coronary atherosclerosis. AJPC open access . @DrEugeneYang nice work @khurramn1

RNAi never had a drug problem, it had a delivery problem. The liver fell years ago. The brain is the last mile, and the wall is finally coming down. Tau is next. New note: The Last Mile to the Brain. $ARWR #Alzheimers #RNAi bioboyscout.com/p/the-last-mil…

Please join us at Hammersmith Hospital on 10 /11 Sep either in person or online Details below imperialendo.co.uk/calman149.htm

#HID2026 Important presentation by @ProfKausikRay at @HeartinDiabetes. ✅ Genes are not destiny. But elevated PRS increases risk across LDL-C. ✅ High Lp(a)? Manage other risk factors aggressively! ✅ Start early - lower risk patients benefit most from LDL ⬇️ @YHandelsmanMD

#HID2026 Such a great panel discussion to conclude the ASCVD in 2026 session at @HeartinDiabetes with @BudoffMd, @ProfKausikRay, and Dr Norman Lepor from @CedarsSinai ➡️ For LDL-C: Lower. Longer. Faster ➡️ Lp(a): Measure in all adults ➡️ The higher the CAC, the lower the LDL

@CircRes Compendium on #Lipoproteins and #CVD #CETP Inhibitors: Back with a New Target ahajrnls.org/4vC1yTf Authored by Drs.Nicholls & colleagues @ProfSNicholls @ajnelson @ProfKausikRay @johnkastelein

inews.co.uk/news/why-peopl… Great coverage of Irene’s paper @khurramn1 @SABOURETCardio @DrDerekConnolly @drpablocorral @pabeda1

Ruvonoflast, an oral NLRP3 inhibitor, provides early, sustained, & reversible reductions in #hsCRP & significantly lowers inflammatory biomarkers IL-6 & fibrinogen in cardiometabolic patients with elevated #ASCVD risk jacc.org/doi/10.1016/j.… #EASCongress2026 #JACC @ProfKausikRay